Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ELIAS HENRY SARKIS

Allopathic & Osteopathic Physicians Psychiatry & Neurology Child & Adolescent Psychiatry

NPI
1285749283
CMS profile
239756
Location
GAINESVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$34,500.24

93 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Honoraria $31,350.00 11
Food and Beverage $1,979.51 70
Travel and Lodging $1,170.73 12

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–93 of 93 matching records. This page contains 43 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ELIAS HENRY SARKIS

NPI 1285749283 · CMS profile ID 239756

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Child & Adolescent Psychiatry

GAINESVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–93 of 93 matching records. This page contains 43 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1285749283?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ELIAS HENRY SARKIS, NPI 1285749283, CMS profile ID 239756. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–93 of 93 matching records. This page contains 43 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1285749283?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). ELIAS HENRY SARKIS, NPI 1285749283, CMS profile ID 239756. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–93 of 93 matching records. This page contains 43 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1285749283?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
ELIAS HENRY SARKIS, NPI 1285749283, CMS profile ID 239756, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–93 of 93 matching records. This page contains 43 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1285749283?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

93 matching records · $34,500.24 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 93 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–93 of 93.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Supernus Pharmaceuticals, Inc. $31.7007/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244883956 CMS
Supernus Pharmaceuticals, Inc. $3,000.0007/31/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1244883958 CMS
Supernus Pharmaceuticals, Inc. $84.0907/31/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1244883960 CMS
Supernus Pharmaceuticals, Inc. $49.0907/31/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1244883962 CMS
Supernus Pharmaceuticals, Inc. $49.1707/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244883964 CMS
Supernus Pharmaceuticals, Inc. $3,000.0007/31/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1244883966 CMS
Supernus Pharmaceuticals, Inc. $84.0907/31/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1244883968 CMS
Supernus Pharmaceuticals, Inc. $49.0907/31/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1244883970 CMS
Alkermes, Inc. $14.6207/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222632508 CMS
Noven Therapeutics, LLC $19.9707/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240399966 CMS
ABBVIE INC. $10.3307/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204066266 CMS
Vanda Pharmaceuticals Inc. $23.4507/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233000963 CMS
ABBVIE INC. $15.5707/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204066260 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.3407/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223821408 CMS
ABBVIE INC. $27.6906/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204066254 CMS
ABBVIE INC. $24.9305/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204066248 CMS
Axsome Therapeutics, Inc. $24.9405/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235721184 CMS
Supernus Pharmaceuticals, Inc. $34.4405/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244883926 CMS
Supernus Pharmaceuticals, Inc. $84.4605/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244883928 CMS
Supernus Pharmaceuticals, Inc. $77.1105/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244883932 CMS
Supernus Pharmaceuticals, Inc. $34.2805/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244883936 CMS
Supernus Pharmaceuticals, Inc. $14.1005/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244883938 CMS
Supernus Pharmaceuticals, Inc. $393.7605/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1244883930 CMS
Supernus Pharmaceuticals, Inc. $3,250.0005/02/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1244883934 CMS
Supernus Pharmaceuticals, Inc. $203.3405/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244883940 CMS
Vanda Pharmaceuticals Inc. $17.9904/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233000961 CMS
Alkermes, Inc. $15.8504/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222632506 CMS
Axsome Therapeutics, Inc. $17.0804/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235590271 CMS
Vertical Pharmaceuticals, LLC $13.8804/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241770349 CMS
ABBVIE INC. $26.6704/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204066243 CMS
Lundbeck LLC $15.4503/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251844475 CMS
Teva Pharmaceuticals USA, Inc. $15.7503/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247275615 CMS
Alkermes, Inc. $26.4403/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222632504 CMS
Axsome Therapeutics, Inc. $110.4603/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235797164 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.8603/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223824844 CMS
Noven Therapeutics, LLC $24.4102/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240399964 CMS
Vanda Pharmaceuticals Inc. $34.4502/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233000959 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $14.8202/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241395093 CMS
Otsuka America Pharmaceutical, Inc. $21.5902/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227481834 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.6202/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223816928 CMS
Bausch Health US, LLC $15.1802/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1239978474 CMS
Neos Therapeutics, LP $17.5201/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206088942 CMS
Noven Therapeutics, LLC $21.7501/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240399970 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $42,015.40 194
PY2020 $16,210.05 84
PY2021 $6,970.11 111
PY2022 $21,189.30 114
PY2023 $18,483.45 93
PY2024 $29,256.12 98
PY2025 $34,500.24 93

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $214,012.98 46
PY2024 Principal investigator $693,209.32 128
PY2023 Recipient $3,600.00 2
PY2023 Principal investigator $947,668.12 205
PY2022 Principal investigator $333,949.20 77
PY2021 Recipient $4,157.00 1
PY2021 Principal investigator $391,143.58 78
PY2020 Recipient $18,390.13 3
PY2020 Principal investigator $512,879.98 238
PY2019 Recipient $84,908.63 12
PY2019 Principal investigator $696,967.76 198

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

46 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $991.48 12/31/2025 Non-covered Recipient Entity
EHS MEDICAL PRACTICE
A 52-Week, Multicenter, Open-Label, Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Subjects with Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder No dispute reported 06/30/2026 1202532456
Principal investigator 2 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,000.00 11/03/2025 Non-covered Recipient Entity
SARKIS CLINICAL TRIALS
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment No dispute reported 06/30/2026 1242365073
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $400.00 10/13/2025 Non-covered Recipient Entity
EHS MEDICAL PRACTICE PA
ITI-007-601 No dispute reported 06/30/2026 1242363743
Principal investigator 1 ACADIA Pharmaceuticals Inc $18,691.55 09/15/2025 Non-covered Recipient Entity
ANZONI
ACP-103-070 No dispute reported 06/30/2026 1245936129
Principal investigator 1 ACADIA Pharmaceuticals Inc $3,478.65 09/15/2025 Non-covered Recipient Entity
ANZONI
ACP-103-070 No dispute reported 06/30/2026 1245936131
Principal investigator 1 ACADIA Pharmaceuticals Inc $5,623.70 09/10/2025 Non-covered Recipient Entity
ANZONI
ACP-103-070 No dispute reported 06/30/2026 1245936077
Principal investigator 1 ABBVIE INC. $3,600.00 08/26/2025 Non-covered Recipient Entity
THE EHS MEDICAL PRACTICE PA
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1202505833
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $12,000.00 08/11/2025 Non-covered Recipient Entity
SARKIS CLINICAL TRIALS
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment No dispute reported 06/30/2026 1242356908
Principal investigator 1 ACADIA Pharmaceuticals Inc $4,392.05 08/04/2025 Non-covered Recipient Entity
ANZONI
ACP-103-070 No dispute reported 06/30/2026 1245935459
Principal investigator 1 ABBVIE INC. $6,000.00 07/22/2025 Non-covered Recipient Entity
THE EHS MEDICAL PRACTICE PA
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1202499106
Principal investigator 1 ABBVIE INC. $3,500.00 07/18/2025 Non-covered Recipient Entity
THE EHS MEDICAL PRACTICE PA
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1202498920
Principal investigator 1 ACADIA Pharmaceuticals Inc $30,821.29 07/07/2025 Non-covered Recipient Entity
ANZONI
ACP-103-069 No dispute reported 06/30/2026 1245934511
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $192.10 07/07/2025 Non-covered Recipient Entity
SARKIS CLINICAL TRIALS
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment No dispute reported 06/30/2026 1242352520
Principal investigator 1 ACADIA Pharmaceuticals Inc $2,450.00 05/12/2025 Non-covered Recipient Entity
ANZONI
ACP-103-069 No dispute reported 06/30/2026 1245934217
Principal investigator 1 ABBVIE INC. $14,032.00 05/07/2025 Non-covered Recipient Entity
THE EHS MEDICAL PRACTICE PA
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder No dispute reported 06/30/2026 1202483651
Principal investigator 1 PFIZER INC. $1,112.99 04/24/2025 Non-covered Recipient Entity
The EHS Medical Practice Pa
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228763053
Principal investigator 1 PFIZER INC. $1,400.00 04/24/2025 Non-covered Recipient Entity
The EHS Medical Practice Pa
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1228776612
Principal investigator 1 ACADIA Pharmaceuticals Inc $21,812.76 04/15/2025 Non-covered Recipient Entity
ANZONI
ACP-103-070 No dispute reported 06/30/2026 1245934061
Principal investigator 1 ACADIA Pharmaceuticals Inc $973.05 04/15/2025 Non-covered Recipient Entity
ANZONI
ACP-103-070 No dispute reported 06/30/2026 1245934063
Principal investigator 1 ACADIA Pharmaceuticals Inc $2,800.00 04/10/2025 Non-covered Recipient Entity
ANZONI
ACP-103-069 No dispute reported 06/30/2026 1245934047
Principal investigator 1 PFIZER INC. $1,000.00 04/04/2025 Non-covered Recipient Entity
The EHS Medical Practice Pa
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228778660
Principal investigator 1 ABBVIE INC. $24,885.00 04/03/2025 Non-covered Recipient Entity
THE EHS MEDICAL PRACTICE PA
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1202473807
Principal investigator 1 PFIZER INC. $138.35 03/27/2025 Non-covered Recipient Entity
The EHS Medical Practice Pa
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1228765706
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $9,500.00 03/19/2025 Non-covered Recipient Entity
EHS MEDICAL PRACTICE PA
ITI-007-601 No dispute reported 06/30/2026 1242338313
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,800.00 03/19/2025 Non-covered Recipient Entity
EHS MEDICAL PRACTICE PA
ITI-007-601 No dispute reported 06/30/2026 1242338315
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $650.00 03/19/2025 Non-covered Recipient Entity
EHS MEDICAL PRACTICE PA
ITI-007-601 No dispute reported 06/30/2026 1242338337
Principal investigator 1 PFIZER INC. $733.55 03/13/2025 Non-covered Recipient Entity
The EHS Medical Practice Pa
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228767161
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,000.00 03/01/2025 Non-covered Recipient Entity
EHS MEDICAL PRACTICE PA DBA SARKIS CLINICAL TRIALS
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment No dispute reported 06/30/2026 1242333256
Principal investigator 1 PFIZER INC. $1,200.00 02/27/2025 Non-covered Recipient Entity
The EHS Medical Practice Pa
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228767290
Principal investigator 1 PFIZER INC. $1,400.00 02/27/2025 Non-covered Recipient Entity
The EHS Medical Practice Pa
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228768075
Principal investigator 1 PFIZER INC. $2,500.00 02/27/2025 Non-covered Recipient Entity
The EHS Medical Practice Pa
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228768083
Principal investigator 1 PFIZER INC. $1,800.00 02/27/2025 Non-covered Recipient Entity
The EHS Medical Practice Pa
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228768463
Principal investigator 1 ACADIA Pharmaceuticals Inc $1,466.10 02/04/2025 Non-covered Recipient Entity
ANZONI
ACP-103-069 No dispute reported 06/30/2026 1245933454
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 02/01/2025 Non-covered Recipient Entity
Sarkis Clinical Trials
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220646965
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 02/01/2025 Non-covered Recipient Entity
Sarkis Clinical Trials
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220646967
Principal investigator 1 Boehringer Ingelheim International GmbH $73.39 02/01/2025 Non-covered Recipient Entity
Sarkis Clinical Trials
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220646969
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,201.00 01/28/2025 Non-covered Recipient Entity
EHS Medical Practice Sarkis Clinical Trials
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220799509
Principal investigator 1 ACADIA Pharmaceuticals Inc $5,450.00 01/21/2025 Non-covered Recipient Entity
ANZONI
ACP-103-069 No dispute reported 06/30/2026 1245933381
Principal investigator 1 ACADIA Pharmaceuticals Inc $264.60 01/13/2025 Non-covered Recipient Entity
ANZONI
ACP-103-070 No dispute reported 06/30/2026 1245933215
Principal investigator 1 ACADIA Pharmaceuticals Inc $2,395.98 01/06/2025 Non-covered Recipient Entity
ANZONI
ACP-103-070 No dispute reported 06/30/2026 1245933121
Principal investigator 1 PFIZER INC. $4,000.00 01/03/2025 Non-covered Recipient Entity
The EHS Medical Practice Pa
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228767327
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 01/01/2025 Non-covered Recipient Entity
Sarkis Clinical Trials
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220646957
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 01/01/2025 Non-covered Recipient Entity
Sarkis Clinical Trials
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220646959
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 01/01/2025 Non-covered Recipient Entity
Sarkis Clinical Trials
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220646961
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 01/01/2025 Non-covered Recipient Entity
Sarkis Clinical Trials
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220646963
Principal investigator 1 Boehringer Ingelheim International GmbH $73.39 01/01/2025 Non-covered Recipient Entity
Sarkis Clinical Trials
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220646971